Page 206 - Haematologica March 2020

H. Kuusanmaki et al.
BCL-2 inhibition by ABT-199 causes on-
target cell death in acute myeloid leukemia.
Cancer Discov. 2014;4(3):362-375.
41. Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5- Azacytidine-sensitizing targets and deter- minants of response in myeloid malignan-
cies. Leukemia. 2014;28(8):1657-1665.
42. Yang T, Kozopas KM, Craig RW. The intra- cellular distribution and pattern of expres- sion of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol.
1995;128(6):1173-1184.
43. DiNardo CD, Rausch CR, Benton C, et al.
Clinical experience with the BCL2- inhibitor venetoclax in combination thera- py for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;
93(3):401-407.
44. Rose D, Haferlach T, Schnittger S,
Perglerová K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31(1):11-17.
45. Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell– induced protection of AML. Blood. 2017;130(6):789-802.
46. Kurtz SE, Eide CA, Kaempf A, et al. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. 2018; 32(9):2025-2028.
47. Kurtz SE, Eide CA, Kaempf A, et al. Molecularly targeted drug combinations
demonstrate selective effectiveness for myeloid- and lymphoid-derived hemato- logic malignancies. Proc Natl Acad Sci U S A. 2017;114(36):E7554-E7563.
48. Daver N, Pollyea DA, Yee KWL, et al. Preliminary results from a Phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobime- tinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R/R) AML. Blood. 2017;130(Suppl 1):813.
49. Lowenberg B, van Putten W, Touw IP, Delwel R, Santini V. Autonomous prolifer- ation of leukemic cells in vitro as a eetermi- nant of Prognosis in adult acute myeloid leukemia. N Engl J Med. 1993;328(9):614- 619.
720
haematologica | 2020; 105(3)